Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
51.72
-0.54 (-1.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
856,072
Open
52.35
Bid (Size)
51.57 (100)
Ask (Size)
52.10 (100)
Prev. Close
52.26
Today's Range
51.62 - 53.21
52wk Range
44.12 - 78.48
Shares Outstanding
78,935,098
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
↗
Today 11:29 EDT
One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
Via
The Motley Fool
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
↗
Today 10:50 EDT
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Via
The Motley Fool
Topics
Intellectual Property
Performance
YTD
-3.8%
-3.8%
1 Month
-4.3%
-4.3%
3 Month
+3.0%
+3.0%
6 Month
+5.8%
+5.8%
1 Year
-0.2%
-0.2%
More News
Read More
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
↗
Today 5:35 EDT
Via
The Motley Fool
Why CRISPR Therapeutics Stock Rocked the Market Last Month
↗
September 08, 2026
Via
The Motley Fool
Where Will CRISPR Therapeutics Stock Be in 5 Years?
↗
September 08, 2026
Via
The Motley Fool
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
↗
September 02, 2026
Via
The Motley Fool
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?
↗
August 21, 2026
Via
The Motley Fool
Topics
ETFs
Stocks
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
↗
August 20, 2026
Via
The Motley Fool
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?
↗
July 30, 2026
Via
The Motley Fool
3 Stocks With the Most Upside by the End of 2026
↗
July 30, 2026
Via
The Motley Fool
Topics
Workforce
3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside
↗
July 28, 2026
Via
The Motley Fool
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
↗
July 22, 2026
Via
The Motley Fool
Topics
ETFs
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
↗
July 20, 2026
Via
The Motley Fool
3 Reasons to Buy CRISPR Therapeutics Stock
↗
July 10, 2026
Via
The Motley Fool
Vertex’s Crinetics Deal Balances Growth with Integration Risk
↗
July 08, 2026
Via
MarketBeat
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
↗
July 08, 2026
Via
The Motley Fool
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now
↗
July 07, 2026
Via
The Motley Fool
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
↗
July 07, 2026
Via
The Motley Fool
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
↗
July 06, 2026
Via
The Motley Fool
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
↗
June 27, 2026
Via
The Motley Fool
The Best Stocks to Invest $1,000 in Right Now
↗
June 22, 2026
Via
The Motley Fool
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year
↗
June 18, 2026
Via
The Motley Fool
The Best Biotech Stocks to Buy in 2026
↗
June 17, 2026
Via
The Motley Fool
Topics
ETFs
Here's How I'd Invest $10,000 Right Now
↗
June 17, 2026
Via
The Motley Fool
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?
↗
June 08, 2026
Via
The Motley Fool
Frequently Asked Questions
Is CRISPR Therapeutics AG - Common Shares publicly traded?
Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
What exchange does CRISPR Therapeutics AG - Common Shares trade on?
CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
What is the current price of CRISPR Therapeutics AG - Common Shares?
The current price of CRISPR Therapeutics AG - Common Shares is 51.72
When was CRISPR Therapeutics AG - Common Shares last traded?
The last trade of CRISPR Therapeutics AG - Common Shares was at 09/11/26 04:00 PM ET
What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
The market capitalization of CRISPR Therapeutics AG - Common Shares is 4.08B
How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
CRISPR Therapeutics AG - Common Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.